. "I, S" . "Looking from the point of risk of development of cancer are most antidiabetic drugs either neutral or lead to mild increase of the risk. Metformin is the only antidiabetic drug, which in retrospective studies decreased the risk of malignant diseases (OR 0,54 \u2013 0,70). In the patients treated with metformin were observed also better results of antitumor treatment. Most studies described also lower risk of pancreatic cancer in diabetic patients treated with metformin. There is a description of patients, treated with metformin from the beginning of pancreatic cancer with prognosis of longer survival compared with those, who were not treated with insulin. On contrary, this is not true, when metformin was started in developer stage of pancreatic cancer. The article gives the survey of contemporary knowledge in this field."@en . "Diabetologie, metabolismus, endokrinologie, v\u00FD\u017Eiva" . "11120" . "\u0160krha, Pavel" . "Metformin a karcinom pankreatu"@cs . "Zat\u00EDmco \u0159ada antidiabetik je z hlediska rizika vzniku malign\u00EDho n\u00E1doru neutr\u00E1ln\u00ED nebo toto riziko m\u00EDrn\u011B zvy\u0161uje, metformin p\u0159edstavuje l\u00E9k, kter\u00FD p\u0159i retrospektivn\u00EDm sledov\u00E1n\u00ED obecn\u011B sni\u017Euje riziko vzniku malign\u00EDch onemocn\u011Bn\u00ED (OR 0,54\u20130,70). U nemocn\u00FDch l\u00E9\u010Den\u00FDch metforminem byly pozorov\u00E1ny i lep\u0161\u00ED v\u00FDsledky protin\u00E1dorov\u00E9 l\u00E9\u010Dby. V p\u0159\u00EDpad\u011B karcinomu pankreatu diabetici l\u00E9\u010Den\u00ED metforminem m\u011Bli ve v\u011Bt\u0161in\u011B prac\u00ED men\u0161\u00ED riziko vzniku n\u00E1doru. Pokud byl metformin pod\u00E1v\u00E1n ji\u017E v za\u010D\u00E1tku vzniku n\u00E1doru, byla snad i lep\u0161\u00ED vyhl\u00EDdka na del\u0161\u00ED dobu p\u0159e\u017Eit\u00ED. To neplat\u00ED tehdy, byl-li metformin nasazen v obdob\u00ED pokro\u010Dil\u00E9ho r\u016Fstu karcinomu pankreatu. \u010Cl\u00E1nek pod\u00E1v\u00E1 liter\u00E1rn\u00ED p\u0159ehled t\u00E9to problematiky." . . . "RIV/00216208:11120/14:43908385!RIV15-MSM-11120___" . "CZ - \u010Cesk\u00E1 republika" . . "17" . . . "Metformin and cancer of pancreas"@en . . "Trnka, Jan" . . "Metformin a karcinom pankreatu"@cs . "Metformin a karcinom pankreatu" . "Metformin and cancer of pancreas"@en . "[ED9859DD0410]" . . "Zat\u00EDmco \u0159ada antidiabetik je z hlediska rizika vzniku malign\u00EDho n\u00E1doru neutr\u00E1ln\u00ED nebo toto riziko m\u00EDrn\u011B zvy\u0161uje, metformin p\u0159edstavuje l\u00E9k, kter\u00FD p\u0159i retrospektivn\u00EDm sledov\u00E1n\u00ED obecn\u011B sni\u017Euje riziko vzniku malign\u00EDch onemocn\u011Bn\u00ED (OR 0,54\u20130,70). U nemocn\u00FDch l\u00E9\u010Den\u00FDch metforminem byly pozorov\u00E1ny i lep\u0161\u00ED v\u00FDsledky protin\u00E1dorov\u00E9 l\u00E9\u010Dby. V p\u0159\u00EDpad\u011B karcinomu pankreatu diabetici l\u00E9\u010Den\u00ED metforminem m\u011Bli ve v\u011Bt\u0161in\u011B prac\u00ED men\u0161\u00ED riziko vzniku n\u00E1doru. Pokud byl metformin pod\u00E1v\u00E1n ji\u017E v za\u010D\u00E1tku vzniku n\u00E1doru, byla snad i lep\u0161\u00ED vyhl\u00EDdka na del\u0161\u00ED dobu p\u0159e\u017Eit\u00ED. To neplat\u00ED tehdy, byl-li metformin nasazen v obdob\u00ED pokro\u010Dil\u00E9ho r\u016Fstu karcinomu pankreatu. \u010Cl\u00E1nek pod\u00E1v\u00E1 liter\u00E1rn\u00ED p\u0159ehled t\u00E9to problematiky."@cs . "Metformin a karcinom pankreatu" . . . "1" . "Hajer, Jan" . "pancreas cancer treatment; pancreas cancer prevention; metformin"@en . "And\u011Bl, Michal" . . . . "4"^^ . "3"^^ . . . "4"^^ . "RIV/00216208:11120/14:43908385" . "28601" . . "1211-9326" . .